ClinVar Miner

Submissions for variant NM_001037.5(SCN1B):c.374G>A (p.Arg125His)

gnomAD frequency: 0.00001  dbSNP: rs759839781
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 5
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
GeneDx RCV000171061 SCV000223625 uncertain significance not provided 2024-10-11 criteria provided, single submitter clinical testing Previously reported in a proband from a pediatric epilepsy cohort; however additional clinical and segregation data were not provided (PMID: 36011376); Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 36011376, 19710327, 28681755)
Labcorp Genetics (formerly Invitae), Labcorp RCV000690875 SCV000818604 uncertain significance Brugada syndrome 5 2024-01-24 criteria provided, single submitter clinical testing This sequence change replaces arginine, which is basic and polar, with histidine, which is basic and polar, at codon 125 of the SCN1B protein (p.Arg125His). This variant is present in population databases (rs759839781, gnomAD 0.0008%). This missense change has been observed in individual(s) with Dravet syndrome and/or epilepsy (PMID: 36011376; Invitae). ClinVar contains an entry for this variant (Variation ID: 190881). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be disruptive. This variant disrupts the p.Arg125 amino acid residue in SCN1B. Other variant(s) that disrupt this residue have been observed in individuals with SCN1B-related conditions (PMID: 19710327, 28681755), which suggests that this may be a clinically significant amino acid residue. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance.
Fulgent Genetics, Fulgent Genetics RCV002485077 SCV002775398 uncertain significance Generalized epilepsy with febrile seizures plus, type 1; Brugada syndrome 5; Atrial fibrillation, familial, 13; Developmental and epileptic encephalopathy, 52 2021-07-29 criteria provided, single submitter clinical testing
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV003235089 SCV003934267 uncertain significance not specified 2023-05-02 criteria provided, single submitter clinical testing Variant summary: SCN1B c.374G>A (p.Arg125His) results in a non-conservative amino acid change located in the Immunoglobulin V-set domain (IPR013106) of the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant was absent in 251484 control chromosomes (gnomAD). The available data on variant occurrences in the general population are insufficient to allow any conclusion about variant significance. c.374G>A has been reported in the literature in an individual affected with epilepsy (example: Blazekovic_2022). This report does not provide unequivocal conclusions about association of the variant with SCN1B-Related Disorders. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Other variants affecting the same amino acid is reported in association with epilepsy in HGMD. The following publication have been ascertained in the context of this evaluation (PMID: 36011376). Three clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 and classified the variant as VUS (n=2) and likely pathogenic (n=1). Based on the evidence outlined above, the variant was classified as uncertain significance.
Clinical Genetics Laboratory, University Hospital Schleswig-Holstein RCV001770132 SCV002011708 likely pathogenic Atrial fibrillation, familial, 13 2021-09-20 no assertion criteria provided clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.